Peter Michael Stein

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

SpePharm AG acquires, registers, and markets medical value medicines for the hospital sector. Its brands include Dantrium IV, Dantrium, Dantamacrin, Lymphoseek and Mugard. The company was founded in 2012 and is headquartered in Luzern, Switzerland.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Norgine BV engages in development and manufacture of pharmaceutical products. It is specialized in gastroenterology, hepatology, cancer, and supportive care. The firms brands include Depoint, Elantan, Emselex, Estraderm, Givalex, Isoket, Nortussine, Provames, Sintrom, Speciafoldine, Surgestone, and Tredemine. The company was founded by Victor Stein in 1906 and is headquartered in Amsterdam, the Netherlands.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Norgine Ventures Management Ltd. acts as an alternative investment manager. The company was founded by Peter Stein in 2012 and is headquartered in Harefield, the United Kingdom.

Norgine BV engages in development and manufacture of pharmaceutical products. It is specialized in gastroenterology, hepatology, cancer, and supportive care. The firms brands include Depoint, Elantan, Emselex, Estraderm, Givalex, Isoket, Nortussine, Provames, Sintrom, Speciafoldine, Surgestone, and Tredemine. The company was founded by Victor Stein in 1906 and is headquartered in Amsterdam, the Netherlands.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Norgine BV engages in development and manufacture of pharmaceutical products. It is specialized in gastroenterology, hepatology, cancer, and supportive care. The firms brands include Depoint, Elantan, Emselex, Estraderm, Givalex, Isoket, Nortussine, Provames, Sintrom, Speciafoldine, Surgestone, and Tredemine. The company was founded by Victor Stein in 1906 and is headquartered in Amsterdam, the Netherlands.

Norgine BV engages in development and manufacture of pharmaceutical products. It is specialized in gastroenterology, hepatology, cancer, and supportive care. The firms brands include Depoint, Elantan, Emselex, Estraderm, Givalex, Isoket, Nortussine, Provames, Sintrom, Speciafoldine, Surgestone, and Tredemine. The company was founded by Victor Stein in 1906 and is headquartered in Amsterdam, the Netherlands.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Norgine Ventures Management Ltd. acts as an alternative investment manager. The company was founded by Peter Stein in 2012 and is headquartered in Harefield, the United Kingdom.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout its long history, they have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. They are committed to developing products not only to treat life-threatening conditions but, importantly, to improve the quality of life for patients with a range of acute and chronic illnesses. They have a long standing tradition of building relationships, based on the highest standards, with patients, physicians, employees, partners and other key stakeholders. In the last fifteen years, they have focused on expanding its pan-European infrastructure, and have moved to strengthen the Research & Development base of the company. In addition to developing, manufacturing and marketing its own pharmaceutical products, Norgine is an ideal partner for companies seeking assistance in the development and launch of innovative pharmaceutical products across Europe. They value its development partnerships as, together with its own in-house product development; they support its growth ambitions and will help to facilitate its continued business expansion. They have the resources to bring products to market on a pan-European or single country basis, combining sales and marketing expertise together with all development, clinical research, and product registration or manufacturing resources that its partners require. In the years ahead Norgine will continue to implement this successful strategy, building on its established infrastructure, strengthening its pan-European presence and collaborating with like-minded companies and organizations.

Norgine BV engages in development and manufacture of pharmaceutical products. It is specialized in gastroenterology, hepatology, cancer, and supportive care. The firms brands include Depoint, Elantan, Emselex, Estraderm, Givalex, Isoket, Nortussine, Provames, Sintrom, Speciafoldine, Surgestone, and Tredemine. The company was founded by Victor Stein in 1906 and is headquartered in Amsterdam, the Netherlands.

Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout its long history, they have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. They are committed to developing products not only to treat life-threatening conditions but, importantly, to improve the quality of life for patients with a range of acute and chronic illnesses. They have a long standing tradition of building relationships, based on the highest standards, with patients, physicians, employees, partners and other key stakeholders. In the last fifteen years, they have focused on expanding its pan-European infrastructure, and have moved to strengthen the Research & Development base of the company. In addition to developing, manufacturing and marketing its own pharmaceutical products, Norgine is an ideal partner for companies seeking assistance in the development and launch of innovative pharmaceutical products across Europe. They value its development partnerships as, together with its own in-house product development; they support its growth ambitions and will help to facilitate its continued business expansion. They have the resources to bring products to market on a pan-European or single country basis, combining sales and marketing expertise together with all development, clinical research, and product registration or manufacturing resources that its partners require. In the years ahead Norgine will continue to implement this successful strategy, building on its established infrastructure, strengthening its pan-European presence and collaborating with like-minded companies and organizations.

SpePharm AG acquires, registers, and markets medical value medicines for the hospital sector. Its brands include Dantrium IV, Dantrium, Dantamacrin, Lymphoseek and Mugard. The company was founded in 2012 and is headquartered in Luzern, Switzerland.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Norgine Ventures Management Ltd. acts as an alternative investment manager. The company was founded by Peter Stein in 2012 and is headquartered in Harefield, the United Kingdom.